The Genomic Edge: How Genomics is Redefining Cancer Drug Trials

SAN DIEGO, CA – January 28, 2026 – A landmark collaboration announced today is set to reshape the landscape of oncology drug development, signaling a pivotal shift from research-grade genomics to front-line clinical application. Bioinformatics firm Inocras revealed it will deploy its advanced whole genome sequencing platforms, CancerVision™ and MRDVision™, within a first-in-human clinical study by Accent Therapeutics for its promising new cancer drug, ATX-295.

This partnership moves beyond traditional trial methodologies by embedding deep, comprehensive genomic analysis directly into the earliest phases of clinical testing. Accent Therapeutics, a biopharmaceutical company pioneering new classes of precision cancer therapies, will leverage Inocras's technology to gain an unprecedented view of tumor dynamics in its Phase 1/2 study of ATX-295, a potential best-in-class inhibitor of the KIF18A protein. The collaboration aims to accelerate the drug's development pathway, offering a new blueprint for how next-generation therapies are evaluated and brought to patients.

A New Blueprint for Clinical Trials

The core of the collaboration lies in the integration of two powerful genomic tools. Inocras’s CancerVision™ platform will be used to perform detailed whole-genome profiling of tumor samples from patients in the trial. This goes far beyond standard gene panels, providing a complete map of the cancer's genetic makeup, including somatic and germline mutations, tumor mutational burden (TMB), microsatellite instability (MSI), and complex structural rearrangements. This comprehensive characterization is critical for understanding which patients are most likely to respond to ATX-295.

Complementing this is MRDVision™, an ultra-sensitive tool for monitoring treatment response. By detecting minute traces of circulating tumor DNA (ctDNA) in a patient's bloodstream—down to one part per million—the platform offers a real-time view of the drug's effectiveness. This allows clinicians to track tumor dynamics during the dose-escalation phase of the trial with extraordinary precision, potentially identifying signs of response or resistance far earlier than conventional imaging methods.

“This collaboration marks an inflection point in how whole genome data drives clinical execution,” said Jehee Suh, CEO of Inocras, in a statement. “By deploying our CancerVision and MRDVision platforms, we are empowering Accent’s team with the comprehensive, ultra-sensitive insights needed to accelerate their groundbreaking ATX-295 program. This partnership underscores that whole genome profiling is no longer just for research; it is a critical tool for next-generation drug development.”

For Accent, the strategic value is clear. “Access to a robust, clinically validated, whole-genome cancer profiling platform such as CancerVision has been critical to accelerating translational insights and clinical execution for our ATX-295 program,” stated Serena Silver, Ph.D., Chief Scientific Officer of Accent Therapeutics. “We are eager to use the insights gained from the Inocras platform to help advance ATX-295 in the clinic.”

Targeting a Critical Cancer Vulnerability

The drug at the center of the trial, ATX-295, represents a novel approach to fighting cancer. It is a highly selective, oral small molecule designed to inhibit KIF18A, a motor protein essential for cell division. While KIF18A is present in healthy cells, it becomes a critical dependency for a specific subset of tumors characterized by chromosomal instability (CIN). These CIN-positive cancer cells, which are notoriously difficult to treat, rely on KIF18A to manage their chaotic cell division process and survive. By inhibiting KIF18A, ATX-295 selectively triggers catastrophic mitotic errors in these cancer cells, leading to their death while largely sparing healthy tissue.

This targeted mechanism holds significant promise for patients with advanced solid tumors, particularly those with high-grade serous ovarian cancer (HGSOC) and triple-negative breast cancer (TNBC), where CIN is prevalent. Recognizing its potential, the U.S. Food and Drug Administration (FDA) has already granted Fast Track designation for ATX-295 in treating advanced platinum-resistant ovarian cancer, a condition with a significant unmet medical need.

The KIF18A inhibitor space is an emerging and competitive frontier in oncology. Other companies, such as Volastra Therapeutics with its candidate Sovilnesib, are also exploring this target, underscoring the scientific community's confidence in its therapeutic potential. Accent's strategy to embed advanced genomics early in its clinical program could provide a crucial edge in navigating this promising but challenging field.

The Power of Whole Genome Intelligence

The Inocras-Accent partnership exemplifies a broader industry trend: the maturation of whole genome sequencing (WGS) from a discovery tool into an indispensable instrument for clinical development. For years, genomic testing in oncology was limited to targeted panels that scanned for a few dozen or hundred known cancer-related genes. While useful, these panels can miss the bigger picture, failing to detect novel mutations, complex structural variants, or the broader genomic signatures that dictate a tumor's behavior and vulnerabilities.

Inocras's CLIA/CAP-certified platforms are designed to overcome these limitations. The CancerVision™ test has demonstrated 100% concordance with established assays like Illumina's TSO500 while also identifying additional, clinically relevant variants. This ability to capture the full genomic context is vital for a biomarker-driven strategy like Accent's, which aims to match the right drug to the right patient based on their unique tumor biology.

Simultaneously, the rise of ultra-sensitive minimal residual disease (MRD) testing is revolutionizing how treatment efficacy is measured. The ability of MRDVision™ to provide a near real-time readout of tumor burden allows for rapid and informed decision-making within a clinical trial. This can help optimize dosing, identify early responders, and de-risk the notoriously expensive and time-consuming process of drug development. By understanding precisely how a tumor is responding at a molecular level, researchers can adapt their strategies much faster than ever before.

Strategic Synergy in a Competitive Landscape

For Accent Therapeutics, this collaboration is not an isolated tactic but a reflection of its core strategy. The company has established itself as a leader in drugging novel targets in the RNA-modifying protein (RMP) space and adjacent areas of high-value biology. With a pipeline that also includes ATX-559, a first-in-class DHX9 inhibitor also in Phase 1/2 trials, Accent has demonstrated a clear focus on pioneering therapies for genetically defined patient populations.

This focus has attracted significant investment, including a $75 million Series C financing round in 2024 with participation from pharmaceutical giants like Bristol Myers Squibb and Johnson & Johnson. The company has also forged major strategic alliances, including a transformational partnership with AstraZeneca. The decision to partner with Inocras aligns perfectly with this biomarker-driven ethos, leveraging specialized, best-in-class technology to maximize the potential of its lead assets.

By integrating deep genomic data at the earliest stages of clinical testing, Accent is not only aiming to accelerate the ATX-295 program but is also building a rich dataset that will yield invaluable insights for its entire pipeline. This forward-thinking approach, where advanced diagnostics and therapeutics are developed in lockstep, represents a powerful model for the future of precision oncology. This integration of deep genomic data at the earliest stages of clinical testing may soon become the standard, fundamentally reshaping the path from laboratory discovery to the patient's bedside.